Circulating T cells to infliximab are detectable mainly in treated patients developing anti‐drug antibodies and hypersensitivity reactions

Antibodies recognizing infliximab (IFX) may develop in a proportion of treated patients, leading to loss of response or hypersensitivity reactions (HRs). T cell response to IFX has been poorly investigated. This paper was addressed to detect IFX‐specific T cells in treated patients with inflammatory...

Descripción completa

Detalles Bibliográficos
Autores principales: Vultaggio, A., Petroni, G., Pratesi, S., Nencini, F., Cammelli, D., Milla, M., Prignano, F., Annese, V., Romagnani, S., Maggi, E., Matucci, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108070/
https://www.ncbi.nlm.nih.gov/pubmed/27569750
http://dx.doi.org/10.1111/cei.12858

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108070/
https://www.ncbi.nlm.nih.gov/pubmed/27569750
http://dx.doi.org/10.1111/cei.12858

Ejemplares similares